Ethics of a partially effective dengue vaccine: Lessons from the Philippines

Dengvaxia, a chimeric yellow fever tetravalent dengue vaccine developed by SanofiPasteur is widely licensed in dengue-endemic countries. In a large cohort study Dengvaxia was found to partially protect children who had prior dengue virus (DENV) infections but sensitized seronegative children to brea...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Vaccine 2020-07, Vol.38 (35), p.5572-5576
Hauptverfasser:	Halstead, Scott B., Katzelnick, Leah C., Russell, Philip K., Markoff, Lewis, Aguiar, Maira, Dans, Leonila R., Dans, Antonio L.
Format:	Artikel
Sprache:	eng
Schlagworte:	Age Antibodies, Viral Child Children Clinical trials Cohort Studies Dengue - prevention & control Dengue hemorrhagic fever Dengue Vaccines - adverse effects Ethics Humans Immunization Infections Informed consent Licenses Medical ethics Philippines Population Safety Serology Surveillance Vaccination Vaccine efficacy Vaccines Vaccines, Attenuated Vector-borne diseases Viruses Yellow fever
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!